sandwich duoset elisa (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
sandwich duoset elisa
Sandwich Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 50 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+ic+sandwich+elisa/Human%2FMouse+Cleaved+Caspase-3+(Asp175)+DuoSet+IC+ELISA/med_rxiv__64898__2026__01__02__25343295-145-12-16
Average 95 stars, based on 50 article reviews
Sandwich Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 50 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/duoset+ic+sandwich+elisa/Human%2FMouse+Cleaved+Caspase-3+(Asp175)+DuoSet+IC+ELISA/med_rxiv__64898__2026__01__02__25343295-145-12-16
Average 95 stars, based on 50 article reviews
sandwich duoset elisa - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Phospho-proteomics:Article Title: Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Article Snippet: Accepted Manuscript Pharmacological evaluation of new bioavailable small molecules targeting Eph/ ephrin interaction Carmine Giorgio, Matteo Incerti, Miriam Corrado, Marco Rusnati, Paola Chiodelli, Simonetta Russo, Donatella Callegari, Francesca Ferlenghi, Vigilio Ballabeni, Elisabetta Barocelli, Alessio Lodola, Massimiliano Tognolini PII: S0006-2952(17)30666-4 DOI: https://doi.org/10.1016/j.bcp.2017.11.002 Reference: BCP 12947 To appear in: Biochemical Pharmacology Received Date: 8 September 2017 Accepted Date: 7 November 2017 Please cite this article as: C. Giorgio, M. Incerti, M. Corrado, M. Rusnati, P. Chiodelli, S. Russo, D. Callegari, F. Ferlenghi, V. Ballabeni, E. Barocelli, A. Lodola, M. Tognolini, Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction, Biochemical Pharmacology (2017), doi: https://doi.org/10.1016/ j.bcp.2017.11.002 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Article Title: Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor Article Snippet: The protein content of supernatant was measured with BCA protein assay kit (Thermo scientific) and standardized to 200 μg/mL. .. EphA2 phosphorylation was measured in cell lysates using a Article Title: Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line. Article Snippet: .. Article Title: UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations Article Snippet: The protein content of supernatant was measured with BCA protein assay kit (Thermo Scientific, Waltham, MA, USA) and standardized to 150 μg·mL −1 . .. Phosphorylation of EphA2, EphB4, VEGFR and EGF receptor (EGFR) in cells EphA2, EphB4, VEGFR2 and EGFR phosphorylation was measured in cell lysates using Article Title: Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. Article Snippet: Lithocholic acid (LCA), a physiological ligand for the nuclear receptor FXR and the G-protein-coupled receptor TGR5, has been recently described as an antagonist of the EphA2 receptor, a key member of the ephrin signalling system involved in tumour growth.. Given the ability of LCA to recognize FXR, TGR5, and EphA2 receptors, we hypothesized that the structural requirements for a small molecule to bind each of these receptors might be similar.. We therefore selected a set of commercially available FXR or TGR5 ligands and tested them for their ability to inhibit EphA2 by targeting the EphA2-ephrin-A1 interface. Article Title: Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties. Article Snippet: The EphA2 receptor has been validated in animal models as new target for treating tumors depending on angiogenesis and vasculogenic mimicry.. In the present work, we extended our current knowledge on structure-activity relationship (SAR) data of two related classes of antagonists of the EphA2 receptor, namely 5b-cholan-24-oic acids and 5b-cholan-24-oyl L-b-homotryptophan conjugates, with the aim to develop new antiangiogenic compounds able to efficiently prevent the formation of blood vessels.. As a result of our exploration, we identified UniPR505, N-[3a-(Ethylcarbamoyl)oxy-5b-cholan-24-oyl]-L-bhomo-tryptophan (compound 14), as a submicromolar antagonist of the EphA2 receptor capable to block EphA2 phosphorylation and to inhibit neovascularization in a chorioallantoic membrane (CAM) assay. Article Title: UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations Article Snippet: The protein content of supernatant was measured with BCA protein assay kit (Thermo Scientific, Waltham, MA, USA) and standardized to 150 μg·mL −1 . .. EphA2, EphB4, VEGFR2 and EGFR phosphorylation was measured in cell lysates using Sandwich ELISA:Article Title: Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Article Snippet: Accepted Manuscript Pharmacological evaluation of new bioavailable small molecules targeting Eph/ ephrin interaction Carmine Giorgio, Matteo Incerti, Miriam Corrado, Marco Rusnati, Paola Chiodelli, Simonetta Russo, Donatella Callegari, Francesca Ferlenghi, Vigilio Ballabeni, Elisabetta Barocelli, Alessio Lodola, Massimiliano Tognolini PII: S0006-2952(17)30666-4 DOI: https://doi.org/10.1016/j.bcp.2017.11.002 Reference: BCP 12947 To appear in: Biochemical Pharmacology Received Date: 8 September 2017 Accepted Date: 7 November 2017 Please cite this article as: C. Giorgio, M. Incerti, M. Corrado, M. Rusnati, P. Chiodelli, S. Russo, D. Callegari, F. Ferlenghi, V. Ballabeni, E. Barocelli, A. Lodola, M. Tognolini, Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction, Biochemical Pharmacology (2017), doi: https://doi.org/10.1016/ j.bcp.2017.11.002 This is a PDF file of an unedited manuscript that has been accepted for publication.. As a service to our customers we are providing this early version of the manuscript.. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Article Title: Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor Article Snippet: The protein content of supernatant was measured with BCA protein assay kit (Thermo scientific) and standardized to 200 μg/mL. .. EphA2 phosphorylation was measured in cell lysates using a Article Title: Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line. Article Snippet: .. Article Title: UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations Article Snippet: The protein content of supernatant was measured with BCA protein assay kit (Thermo Scientific, Waltham, MA, USA) and standardized to 150 μg·mL −1 . .. Phosphorylation of EphA2, EphB4, VEGFR and EGF receptor (EGFR) in cells EphA2, EphB4, VEGFR2 and EGFR phosphorylation was measured in cell lysates using Article Title: Target hopping as a useful tool for the identification of novel EphA2 protein-protein antagonists. Article Snippet: Lithocholic acid (LCA), a physiological ligand for the nuclear receptor FXR and the G-protein-coupled receptor TGR5, has been recently described as an antagonist of the EphA2 receptor, a key member of the ephrin signalling system involved in tumour growth.. Given the ability of LCA to recognize FXR, TGR5, and EphA2 receptors, we hypothesized that the structural requirements for a small molecule to bind each of these receptors might be similar.. We therefore selected a set of commercially available FXR or TGR5 ligands and tested them for their ability to inhibit EphA2 by targeting the EphA2-ephrin-A1 interface. Article Title: Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties. Article Snippet: The EphA2 receptor has been validated in animal models as new target for treating tumors depending on angiogenesis and vasculogenic mimicry.. In the present work, we extended our current knowledge on structure-activity relationship (SAR) data of two related classes of antagonists of the EphA2 receptor, namely 5b-cholan-24-oic acids and 5b-cholan-24-oyl L-b-homotryptophan conjugates, with the aim to develop new antiangiogenic compounds able to efficiently prevent the formation of blood vessels.. As a result of our exploration, we identified UniPR505, N-[3a-(Ethylcarbamoyl)oxy-5b-cholan-24-oyl]-L-bhomo-tryptophan (compound 14), as a submicromolar antagonist of the EphA2 receptor capable to block EphA2 phosphorylation and to inhibit neovascularization in a chorioallantoic membrane (CAM) assay. Article Title: UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations Article Snippet: The protein content of supernatant was measured with BCA protein assay kit (Thermo Scientific, Waltham, MA, USA) and standardized to 150 μg·mL −1 . .. EphA2, EphB4, VEGFR2 and EGFR phosphorylation was measured in cell lysates using |
